Phosphorothioates, essential components of therapeutic oligonucleotides.
about
siRNA Versus miRNA as Therapeutics for Gene SilencingRNAs Containing Modified Nucleotides Fail To Trigger RIG-I Conformational Changes for Innate Immune SignalingStereospecific Effects of Oxygen-to-Sulfur Substitution in DNA Phosphate on Ion Pair Dynamics and Protein-DNA AffinityChemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells.The Toolbox for Modified Aptamers.Thermodynamic Features of Structural Motifs Formed by β-L-RNAEnhancing antisense efficacy with multimers and multi-targeting oligonucleotides (MTOs) using cleavable linkers.Short-interference RNAs: becoming medicines.Synthetic CRISPR RNA-Cas9-guided genome editing in human cellsThe Cancer Genome Atlas Analysis Predicts MicroRNA for Targeting Cancer Growth and Vascularization in Glioblastoma.Stabilin-1 and Stabilin-2 are specific receptors for the cellular internalization of phosphorothioate-modified antisense oligonucleotides (ASOs) in the liver.The delivery of therapeutic oligonucleotidesSplice-switching antisense oligonucleotides as therapeutic drugsAntisense Oligonucleotides: Treatment Strategies and Cellular Internalization.Therapeutic oligonucleotides with polyethylene glycol modifications.Status and Prospects of Aptamers as Drug Components.Oligonucleotide therapeutics: chemistry, delivery and clinical progress.A cytoplasmic pathway for gapmer antisense oligonucleotide-mediated gene silencing in mammalian cells.The Chemistry of the Noncanonical Cyclic Dinucleotide 2'3'-cGAMP and Its Analogs.Application of modified antisense oligonucleotides and siRNAs as antiviral drugs.Advancement of the Emerging Field of RNA Nanotechnology.The chemical evolution of oligonucleotide therapies of clinical utility.Chemical synthesis of RNA with site-specific methylphosphonate modifications.Vector-independent transmembrane transport of oligodeoxyribonucleotides involves p38 mitogen activated protein kinase phosphorylation.In What Ways Do Synthetic Nucleotides and Natural Base Lesions Alter the Structural Stability of G-Quadruplex Nucleic Acids?Nucleic acids: function and potential for abiogenesis.Phosphodiester backbone of the CpG motif within immunostimulatory oligodeoxynucleotides augments activation of Toll-like receptor 9.Amide linkages mimic phosphates in RNA interactions with proteins and are well tolerated in the guide strand of short interfering RNAs.Therapeutic targeting of non-coding RNAs in cancer.Advances in therapeutic bacterial antisense biotechnology.Systematic editing of synthetic RIG-I ligands to produce effective antiviral and anti-tumor RNA immunotherapies.Using Genome Sequence to Enable the Design of Medicines and Chemical Probes.Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs.Synthesis and cytotoxic activity of novel acyclic nucleoside analogues with functionality in click chemistry.Comparison of partially and fully chemically-modified siRNA in conjugate-mediated delivery in vivo.Receptor-Mediated Uptake of Phosphorothioate Antisense Oligonucleotides in Different Cell Types of the Liver.Oligonucleotide modifications enhance probe stability for single cell transcriptome in vivo analysis (TIVA).Development of Phosphorothioate DNA and DNA Thioaptamers.Chemically Modified Cpf1-CRISPR RNAs Mediate Efficient Genome Editing in Mammalian Cells.Molecular mechanism of diabetic cardiomyopathy and modulation of microRNA function by synthetic oligonucleotides.
P2860
Q26786876-03621F85-40B5-4B36-9BEA-56F8833421F1Q27468676-FF2CDD6A-D450-4F8F-98D7-6FB505FCA170Q27708987-4E340066-4489-4AEF-99BA-5875E516F5C9Q34482784-8BE23ADC-01A9-4734-A177-CA57996C0690Q35852997-C7B7C502-944A-48D8-BBD2-AFF7693915FAQ35933327-82C4AA0F-3624-4038-906C-32AF23850B54Q36228096-1A383968-7AA5-4BC8-AE9C-BA2C5AA1DA72Q36347546-DFCEE18C-A126-4189-935A-62855A484AF2Q36419827-BB65545C-2C8C-4257-863B-1A267E669A42Q36756817-870E61E8-23B9-47F1-A7A3-D8F0F28A4636Q36775577-971441D0-4AB6-4CD7-899F-F4457987DC2BQ37210936-F95EB505-04C1-4F06-873D-251E42A60126Q37211004-2193B04F-BE95-4DE3-B3C3-15DB14333EF4Q37733136-60F7279C-DBFA-469B-AD38-3015E2000927Q38296021-FD4F0147-09BD-4BFD-9780-F741C57108D6Q38488502-8719E831-DC50-4E66-B577-F80E39B90A69Q38618638-7CEF7833-C923-49C3-964B-BDEBA3A5B9CEQ38830548-04F5EF7E-8A8D-412D-8F3B-2870922C7499Q38890557-23E95AC5-88D1-47E7-B987-F6CED816FB3FQ38962711-6B965BFE-3C15-4C43-BDDE-92BCB3A99A11Q39065708-5B5DA6E6-FF4A-4B01-B582-8430394F4E28Q39154511-9621D9FE-83B5-4CBD-8695-9ABFF00D1AAAQ42290462-BB52B0C7-C91F-45EE-A654-9315C2915909Q42659834-03E4C76B-A435-4643-9795-D21DF908942BQ45742012-1ED28F16-166C-4FD7-809F-66B007F8A564Q46242768-9FCE916A-5464-4D02-B08D-063126A7B81FQ46259445-F8506374-6392-4369-BD0D-F0015D50D7C7Q47222077-2EA549E4-FEE0-487C-88E0-77A9971CCB7BQ47292099-FC7844F4-5569-4062-8772-5B8AE3B80C25Q47325247-5878F71B-7177-4B0F-A108-E141CEF9A6F3Q47548653-2F510BC1-F407-4AE5-975C-A33447D6F44EQ48263612-73A619FF-96E2-41BD-B0B4-F18CB23B4ACDQ48569299-0F33AAE2-4B1B-4DEB-ACE7-702B6ADE6EDFQ50035154-D88EDF18-B212-4BE5-8B3E-D48D66FC3A30Q50061759-32A9335E-DB80-4DBB-AD0A-42AD774B8D91Q50100050-92462188-16E5-4D83-B298-B1F227220550Q50101001-4B937C52-1A6E-4DB8-A0B9-9BCBC69219B9Q50893422-2F712FC7-9411-4866-9BC8-CC9ECC6E7884Q52431512-0152F084-8FA0-42BA-B158-33D40B179891Q52642353-584AEB02-A4DC-48DF-9C9E-1184C14720E8
P2860
Phosphorothioates, essential components of therapeutic oligonucleotides.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Phosphorothioates, essential components of therapeutic oligonucleotides.
@en
type
label
Phosphorothioates, essential components of therapeutic oligonucleotides.
@en
prefLabel
Phosphorothioates, essential components of therapeutic oligonucleotides.
@en
P356
P1476
Phosphorothioates, essential components of therapeutic oligonucleotides.
@en
P2093
Fritz Eckstein
P304
P356
10.1089/NAT.2014.0506
P577
2014-12-01T00:00:00Z